Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva

This article was originally published in The Pink Sheet Daily

Executive Summary

Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.

You may also be interested in...



Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start

Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.

AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine

Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.

AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine

Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.

Related Content

Topics

UsernamePublicRestriction

Register

PS068557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel